Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer

(2009) John M. Varlotto et al.   CANCER

Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer

(2009) A. Takano et al.   CANCER RESEARCH

An Essential Epitope of Anti-MUC1 Monoclonal Antibody KL-6 Revealed by Focused Glycopeptide Library

(2009) Naoki Ohyabu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

(2008) Nobuhisa Ishikawa et al.   INTERNATIONAL JOURNAL OF CANCER

Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome

(2008) T. Nakashima et al.   JOURNAL OF INTERNAL MEDICINE

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers

(2008) Hisao Asamura et al.   Journal of Thoracic Oncology